Dmytro Horodetskyi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Dmytro Horodetskyi has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Serhii O. Soloviov
Shupyk National Healthcare University of Ukraine, Kyiv
2 shared publications - L. Yu. Babintseva
Shupyk National Healthcare University of Ukraine
1 shared publication - Marina Sidorenko
Faculty of Natural Sciences, Vytautas Magnus University, 53361 Kaunas, Lithuania
1 shared publication - Mohamad Saifudin Hakim
Department of Biology and Immunology, College of Medicine, Qassim University, Buraydah, Saudi Arabia
1 shared publication - Mykhailo Smetiukh
National Technical University of Ukraine «Igor Sikorsky Kyiv Polytechnic Institute», Kyiv, Ukraine
1 shared publication - Olena Kovaliuk
Shupyk National Healthcare University of Ukraine, Kyiv
1 shared publication
Latest Publications
- Open Access
- 26 March 2026
- Published by Igor Sikorsky Kyiv Polytechnic Institute in Innovative Biosystems and Bioengineering
- Vol. 10 (1) , 37-54
Value of Information Analysis in the Pharmacoeconomic Evaluation of Diagnostic Technologies for Respiratory Viral Infections
Background. Respiratory infections remain a major global health burden with significant economic impact. The di-versity of viral pathogens and variability in diagnostic approaches complicate etiological verification in laboratory practice. As diagnostic technologies evolve, there is a growing need for economically justified approaches that integrate analytical performance, operational characteristics, and costs. Value of Information (VOI) analysis provides a formal framework for evaluating the impact of uncertainty on decision-making. Objective. To develop and apply a methodology for assessing the cost-utility and value of information of diagnostic technologies for viral respiratory infections from a laboratory perspective. Methods. The study compared immunochromatographic rapid tests and PCR-based diagnostics for viral infections. Diagnostic utility was quantified using expert elicitation based on four operational criteria: automation, turnaround time, reproducibility, and accessibility. A multi-criteria decision-tree model was constructed, incorporating sensitivity, specificity, diagnostic spectrum, and cost parameters. Uncertainty was modeled using beta and gamma distributions. The framework enabled estimation of expected utility, Net Monetary Benefit (NMB), Expected Value of Perfect Infor-mation (EVPI), and Expected Value of Sample Information (EVSI). Results. A multi-criteria cost-utility methodology for evaluating etiological diagnostic technologies was developed and applied. Within the defined model, PCR-based diagnostics demonstrated higher expected utility, primarily due to their broader diagnostic spectrum and higher analytical sensitivity. In probabilistic simulations (10,000 iterations), PCR showed an average positive Net Monetary Benefit of approximately $854 per clinical sample compared to rapid tests. VOI analysis indicated low decision uncertainty, with EVPI estimated at $0.25 per patient. EVPPI for the diagnostic spectrum of PCR was negligible, and EVSI reached a maximum of $2.69 at a sample size of 40, suggesting limited addi-tional value of further data collection under current assumptions. Conclusions. The integration of multi-criteria cost-utility modelling with VOI analysis provides a consistent frame-work for evaluating diagnostic technologies in laboratory medicine. Within the assumptions of the model, PCR-based diagnostics demonstrated higher economic utility compared to rapid tests. However, the results should be interpreted within the defined laboratory perspective and modeling assumptions, including limitations related to the diagnostic spectrum of rapid tests and the absence of downstream clinical outcomes. The proposed approach supports evidence-based and economically justified selection of diagnostic technologies under uncertainty.
- 26 March 2026
- Published by Igor Sikorsky Kyiv Polytechnic Institute in Innovative Biosystems and Bioengineering
- Vol. 10 (1) , 37-54
Open AccessValue of Information Analysis in the Pharmacoeconomic Evaluation of Diagnostic Technologies for Respiratory Viral Infections
Background. Respiratory infections remain a major global health burden with significant economic impact. The di-versity of viral pathogens and variability in diagnostic approaches complicate etiological verification in laboratory practice. As diagnostic technologies evolve, there is a growing need for economically justified approaches that integrate analytical performance, operational characteristics, and costs. Value of Information (VOI) analysis provides a formal framework for evaluating the impact of uncertainty on decision-making. Objective. To develop and apply a methodology for assessing the cost-utility and value of information of diagnostic technologies for viral respiratory infections from a laboratory perspective. Methods. The study compared immunochromatographic rapid tests and PCR-based diagnostics for viral infections. Diagnostic utility was quantified using expert elicitation based on four operational criteria: automation, turnaround time, reproducibility, and accessibility. A multi-criteria decision-tree model was constructed, incorporating sensitivity, specificity, diagnostic spectrum, and cost parameters. Uncertainty was modeled using beta and gamma distributions. The framework enabled estimation of expected utility, Net Monetary Benefit (NMB), Expected Value of Perfect Infor-mation (EVPI), and Expected Value of Sample Information (EVSI). Results. A multi-criteria cost-utility methodology for evaluating etiological diagnostic technologies was developed and applied. Within the defined model, PCR-based diagnostics demonstrated higher expected utility, primarily due to their broader diagnostic spectrum and higher analytical sensitivity. In probabilistic simulations (10,000 iterations), PCR showed an average positive Net Monetary Benefit of approximately $854 per clinical sample compared to rapid tests. VOI analysis indicated low decision uncertainty, with EVPI estimated at $0.25 per patient. EVPPI for the diagnostic spectrum of PCR was negligible, and EVSI reached a maximum of $2.69 at a sample size of 40, suggesting limited addi-tional value of further data collection under current assumptions. Conclusions. The integration of multi-criteria cost-utility modelling with VOI analysis provides a consistent frame-work for evaluating diagnostic technologies in laboratory medicine. Within the assumptions of the model, PCR-based diagnostics demonstrated higher economic utility compared to rapid tests. However, the results should be interpreted within the defined laboratory perspective and modeling assumptions, including limitations related to the diagnostic spectrum of rapid tests and the absence of downstream clinical outcomes. The proposed approach supports evidence-based and economically justified selection of diagnostic technologies under uncertainty.
- Open Access
- 29 December 2025
- Published by Igor Sikorsky Kyiv Polytechnic Institute in KPI Science News
- Vol. 141 (4)
DECISION MAKING IN ANTI-CORONAVIRUS DRUG DISCOVERY: MATHEMATICAL MODELING AND VALUE OF INFORMATION ANALYSIS
Background. The process of preclinical evaluation of antiviral medications often consists of multiple stages, each containing substantial uncertainties. Traditional methods for screening the compounds often lack structured means for optimizing the decision-making and calculating the feasibility and risks of transitions between all of the stages. Thus, there appears to be a problem with the inefficient selection of promising antiviral molecules, which subsequently increases the probability of choosing suboptimal research trajectories. Objective. To develop a computational framework for optimizing of the transition between stages in preclinical antiviral testing. The system focuses on the integration of decision trees and Markov models in order to include effectiveness, risks and the value of additional information into assessment, supporting an in-depth planning of preclinical research pipelines. Methods. Experimental data from molecular docking, cytotoxicity CD50, and antiviral activity IC50 were used in a multi-stage evaluation system with CTI ≥ 4 being the criterion for progression into further stages. Decision trees provided the explicit rules for advancement of the compounds, while Markov models added context for building sequential strategies under uncertainty and quantified the feasibility of movement to the next stage. Value of information analysis added the assessment of the expected benefit of additional data. Results. The developed framework consistently produced reliable technical results. The decision used in CTI ≥ 4.0 prediction stage demonstrated a conservative classification pattern, correctly identifying compounds with high therapeutic potential while missing some effective candidates. The Markov model showed steadily increasing state values in docking, cytotoxicity, and antiviral testing phases that confirmed the growth of expected utility. Value of information analysis highlighted that the largest gain occurred after antiviral activity testing. Conclusions. The study showed that both decision trees and Markov models capture different but complementary aspects of the preclinical evaluation process. Decision trees provide interpretable set of rules that formalize how molecular docking and cytotoxicity measurement influence the progression of compounds, while their limited sensitivity at the CTI threshold highlighted the complexity of prediction the final success of the evaluated compounds. The Markov model simulations showed that the full three-stage pipeline is justified and that progression decisions are influenced by both uncertainty and experimental cost. The value of information analysis clarify the importance of each stage, helping to emphasize the role of antiviral activity data in reducing uncertainty. These findings support the integration of analytic methods for improving the structure, transparency and efficiency of antiviral preclinical research.
- 29 December 2025
- Published by Igor Sikorsky Kyiv Polytechnic Institute in KPI Science News
- Vol. 141 (4)
Open AccessDECISION MAKING IN ANTI-CORONAVIRUS DRUG DISCOVERY: MATHEMATICAL MODELING AND VALUE OF INFORMATION ANALYSIS
Background. The process of preclinical evaluation of antiviral medications often consists of multiple stages, each containing substantial uncertainties. Traditional methods for screening the compounds often lack structured means for optimizing the decision-making and calculating the feasibility and risks of transitions between all of the stages. Thus, there appears to be a problem with the inefficient selection of promising antiviral molecules, which subsequently increases the probability of choosing suboptimal research trajectories. Objective. To develop a computational framework for optimizing of the transition between stages in preclinical antiviral testing. The system focuses on the integration of decision trees and Markov models in order to include effectiveness, risks and the value of additional information into assessment, supporting an in-depth planning of preclinical research pipelines. Methods. Experimental data from molecular docking, cytotoxicity CD50, and antiviral activity IC50 were used in a multi-stage evaluation system with CTI ≥ 4 being the criterion for progression into further stages. Decision trees provided the explicit rules for advancement of the compounds, while Markov models added context for building sequential strategies under uncertainty and quantified the feasibility of movement to the next stage. Value of information analysis added the assessment of the expected benefit of additional data. Results. The developed framework consistently produced reliable technical results. The decision used in CTI ≥ 4.0 prediction stage demonstrated a conservative classification pattern, correctly identifying compounds with high therapeutic potential while missing some effective candidates. The Markov model showed steadily increasing state values in docking, cytotoxicity, and antiviral testing phases that confirmed the growth of expected utility. Value of information analysis highlighted that the largest gain occurred after antiviral activity testing. Conclusions. The study showed that both decision trees and Markov models capture different but complementary aspects of the preclinical evaluation process. Decision trees provide interpretable set of rules that formalize how molecular docking and cytotoxicity measurement influence the progression of compounds, while their limited sensitivity at the CTI threshold highlighted the complexity of prediction the final success of the evaluated compounds. The Markov model simulations showed that the full three-stage pipeline is justified and that progression decisions are influenced by both uncertainty and experimental cost. The value of information analysis clarify the importance of each stage, helping to emphasize the role of antiviral activity data in reducing uncertainty. These findings support the integration of analytic methods for improving the structure, transparency and efficiency of antiviral preclinical research.